STOCK TITAN

ANI Pharmaceuticals to Present at the Piper Sandler 33rd Annual Healthcare Conference 2021

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

BAUDETTE, Minn.--(BUSINESS WIRE)-- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present virtually at the Piper Sandler 33rd Annual Healthcare Conference 2021 as follows:

Date:

Monday, November 22, 2021

Time/On Demand:

10:00 a.m. ET

Webcast: https://pipersandler.zoom.us/rec/play/64bSMhpWNru89rAZwgbw_bbk5hNSzXKCBmCoMBP2qXNhF2h83k_wp6c7HmRongJQjr_nHxDjHPMgg4T6.4mLgs_b6Am4vVU6-

The webcast will be accessible on demand and archived for 90 days thereafter, via the Company’s website at www.anipharmaceuticals.com, under the Investors section.

ANI Pharmaceuticals will be participating in 1x1 meetings. Meetings can be requested exclusively via Piper Sandler.

About ANI

ANI Pharmaceuticals is a diversified bio-pharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. For more information, please visit www.anipharmaceuticals.com.

Investor Relations:

Lisa M. Wilson, In-Site Communications, Inc.

T: 212-452-2793

E: lwilson@insitecony.com

Source: ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals, Inc.

NASDAQ:ANIP

ANIP Rankings

ANIP Latest News

ANIP Stock Data

1.41B
15.04M
11.2%
75.52%
0.94%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
BAUDETTE

About ANIP

ani pharmaceuticals is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. we focus on niche and high barrier to entry opportunities including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. our two pharmaceutical manufacturing facilities located in baudette, minnesota are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. our objective is to create long term shareholder value by building a sustainable and growing base business in generic and mature brand pharmaceutical products while advancing an opportunity to re-commercialize cortrophin gel and cortrophin-zinc.